In the context of complete cICB regimen (3 i.p. injections over a 6-day period), 3HBpo boosted the tumor growth–inhibitory activity of cICB, prolonging overall survival of almost 60% of RET tumor bearers (Figure 6D). This evidence concerns the gene RET and neoplasm.